HonCode

Go Back   HER2 Support Group Forums > Clinical Trials
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 12-29-2006, 07:15 AM   #1
eric
Senior Member
 
Join Date: Sep 2005
Posts: 589
ARRY-520: KSP inhibitor

http://denver.dbusinessnews.com/show...&newsid=101604

Array BioPharma’s KSP Inhibitor for Cancer to Advance into Human Clinical Trials Phase 1 Trial Expected to Commence in Early 2007Denver - Denver -- Array BioPharma Inc. (NASDAQ: ARRY) filed an Investigational New Drug (IND) application for ARRY-520 with the U.S. Food & Drug Administration and is now able to proceed with human clinical studies. ARRY-520 is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human solid tumors and human leukemias, often leading to durable responses.

Array plans to commence the Phase 1 clinical trial at three academic medical centers in the United States. The open-label, dose-escalation trial is designed to evaluate the safety and tolerability and pharmacokinetics of ARRY-520 following intravenous administration to patients with advanced cancer. In addition, the trial is designed to examine indicators of therapeutic activity in these patients.

“Advancing ARRY-520, our small molecule KSP inhibitor, into clinical trials is a significant achievement for Array and marks our fourth drug to enter clinical development during 2006 and fifth drug overall,” said Kevin Koch, Ph.D., President and Chief Scientific Officer. “We’ve now achieved our goal of having five drugs in clinical development by the end of 2006.”

About Array BioPharma:
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. Our proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important protein targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.

Forward-Looking Statement:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties, including those discussed in our annual report filed on form 10-K for the year ended June 30, 2006, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to continue to fund and successfully progress internal research efforts and to create effective, commercially viable drugs, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities, our ability to out-license our proprietary candidates on favorable terms, risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates, the ability of our collaborators and of Array to meet objectives tied to milestones and royalties, and our ability to attract and retain experienced scientists and management. We are providing this information as of December 28, 2006. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.





Posted on:
Friday, December 29, 2006 01:12 AM
eric is offline   Reply With Quote
Old 05-05-2009, 10:17 AM   #2
Rich66
Senior Member
 
Rich66's Avatar
 
Join Date: Feb 2008
Location: South East Wisconsin
Posts: 3,431
http://www.businesswire.com/portal/s...27&newsLang=en

ARRY-543 - ErbB-2 / EGFR inhibitor for solid tumors: Array continued its Phase 1b trial of ARRY-543 in combination with Xeloda® (capecitabine) in patients with solid tumors. Array initiated two additional Phase 1b trials, in combination with Taxotere® (docetaxel) and Gemzar® (gemcitabine).
AACR Highlights: Preliminary results presented on Array’s Phase 1 trial showed that ARRY-543 was generally well-tolerated and demonstrated evidence of tumor regression and prolonged stable disease in EGFR- and ErbB2-expressing cancers. Of the confirmed patients with ErbB2-positive metastatic breast cancer treated with ARRY-543, 63 percent achieved stable disease for 16 weeks or longer. Twenty one patients were evaluated: 12 had available biopsies and eight were confirmed ErbB2-positive. Clinical benefit was demonstrated in five of these eight patients and patients with confirmed co-expression of ErbB2 and EGFR tended to have the best clinical benefit. In patients with other cancers shown to express ErbB family members, three patients, with ovarian cancer, cervical cancer and cholangiocarcinoma, respectively, treated with ARRY-543 also achieved stable disease for 16 weeks or more; the patient with cholangiocarcinoma experienced a tumor marker response that was accompanied by a 25 percent regression of target lesions.

ARRY-380 – ErbB-2 inhibitor for cancer: Patient recruitment in a Phase 1 trial of ARRY-380, an oral, selective ErbB-2 inhibitor, remains on track to complete in 2009. The trial is designed to evaluate the safety, maximum tolerated dose, and pharmacokinetics of ARRY-380 in cancer patients.
Rich66 is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 04:22 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2018, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter